LivaNova's RECOVER Clinical Study Did Not Meet Its Primary Endpoint For The Unipolar Cohort, Says Statistical Significance Was Achieves In Select Secondary Endpoints
Portfolio Pulse from Benzinga Newsdesk
LivaNova's RECOVER clinical study did not meet its primary endpoint for the unipolar cohort, but achieved statistical significance in select secondary endpoints.
June 06, 2024 | 1:05 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
LivaNova's RECOVER clinical study did not meet its primary endpoint for the unipolar cohort, which could negatively impact investor sentiment. However, achieving statistical significance in select secondary endpoints may provide some positive outlook.
The failure to meet the primary endpoint is likely to be viewed negatively by investors, potentially leading to a short-term decline in stock price. However, the achievement of statistical significance in select secondary endpoints may mitigate some of the negative impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100